Improving cell line development efficiency with AbZelectPRO

Drug developers are often under pressure to rapidly reach investigational new drug (IND) application and demonstrate a return on investment. But on the pathway to IND, cell line development (CLD) is a common bottleneck. Explore how Abzena’s AbZelectPRO™ platform offers a solution by streamlining CLD to achieve lead candidate sequence to research cell bank generation timelines of 10 weeks and de-risking future processes for improved efficiency.